Dyne Therapeutics, Inc. (DYN) Key Metrics
DYN valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $2.66B
- Enterprise value
- $2.35B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- 0.19
- Price / sales
- —
- Price / book
- 4.3 10-yr median 2.7
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.12
DYN key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsDYN valuation Price multiples at each fiscal year-end price.
Price / book−26.6%
2.6
2025 · hover or tap a bar for each year
20162025
Free cash flow yield−2.8 pts
−16.1%
2025 · hover or tap a bar for each year
20162025
DYN returns How much profit the business earns on the capital it uses.
Return on equity+32.3 pts
−55.7%
2025 · hover or tap a bar for each year
20162025
Return on assets+26.6 pts
−47.5%
2025 · hover or tap a bar for each year
20162025
Asset turnover
0.00
2025 · hover or tap a bar for each year
20162025
DYN per-share figures Results divided by the shares outstanding at year-end.
Revenue per share
$0.00
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$3.47
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$3.15
2025 · hover or tap a bar for each year
20162025
Book value per share+13.1%
$7.57
2025 · hover or tap a bar for each year
20162025
Shares outstanding+36.4%
128.4M
2025 · hover or tap a bar for each year
20162025
DYN financial health Debt, liquidity and how easily interest is covered.
Debt / equity−45.2%
0.02
2025 · hover or tap a bar for each year
20162025
Net debt−$472.0M
−$1.09B
2025 · hover or tap a bar for each year
20162025
Current ratio+42.6%
22.25
2025 · hover or tap a bar for each year
20162025
Interest coverage
-75.6
2025 · hover or tap a bar for each year
20162025
Debt / assets−50.8%
0.02
2025 · hover or tap a bar for each year
20162025
DYN efficiency & capital use Working capital cycle and where the cash goes.
Days payables outstanding−1,096 days
1,304 days
2025 · hover or tap a bar for each year
20162025
DYN valuation history
Fiscal year-endToday10-year median
DYN returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
DYN debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
DYN cash returned to shareholders
DividendsBuybacksFree cash flow
DYN price vs earnings per share
Share price at year-endEPS (right axis)
DYN key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $2.51B | $2.22B | $793.8M | $602.4M | $605.1M | $992.6M | — | — | — | — |
| Enterprise value | $1.42B | $1.60B | $698.1M | $376.9M | $261.2M | $647.3M | — | — | — | — |
| Price / book | 2.6 | 3.5 | 8.7 | 2.4 | 1.6 | 2.9 | — | — | — | — |
| Earnings yield | −17.8% | −14.3% | −29.7% | −27.4% | −24.7% | −5.9% | — | — | — | — |
| Free cash flow yield | −16.1% | −13.3% | −23.8% | −26.0% | −20.4% | −4.8% | — | — | — | — |
| Share price at fiscal year-end | $19.56 | $23.56 | $13.30 | $11.59 | $11.89 | $21.00 | — | — | — | — |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | $3.12 | $10.59 |
| Earnings per share | −$3.47 | −$3.37 | −$3.95 | −$3.18 | −$2.93 | −$1.24 | −$0.30 | — | $0.47 | −$9.61 |
| Operating cash flow per share | −$3.14 | −$3.11 | −$3.15 | −$2.96 | −$2.35 | −$0.98 | −$0.26 | — | $3.61 | $5.24 |
| Free cash flow per share | −$3.15 | −$3.13 | −$3.16 | −$3.02 | −$2.42 | −$1.01 | −$0.30 | — | $2.23 | $2.71 |
| Cash per share | $8.65 | $6.82 | $2.06 | $4.93 | $7.40 | $7.31 | $0.32 | — | $2.45 | $14.78 |
| Book value per share | $7.57 | $6.69 | $1.53 | $4.86 | $7.23 | $7.24 | $0.31 | — | $11.73 | $15.83 |
| Tangible book value per share | $7.57 | $6.69 | $1.53 | $4.86 | $7.23 | $7.24 | $0.31 | — | $6.81 | $9.34 |
| Dividends per share | — | — | — | — | — | — | — | — | $0.14 | $0.17 |
| Capex per share | $0.01 | $0.03 | $0.01 | $0.06 | $0.07 | $0.02 | $0.04 | — | $1.38 | $2.53 |
| Debt per share | $0.16 | $0.25 | $0.46 | $0.59 | $0.64 | — | — | — | $52.06 | $69.60 |
| Shares outstanding | 128.4M | 94.1M | 59.7M | 52.0M | 50.9M | 47.3M | 45.4M | — | 162.0M | 129.0M |
| Change in shares outstanding | +36.4% | +57.7% | +14.8% | +2.1% | +7.7% | +4.1% | — | — | +25.6% | +2.4% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −55.7% | −88.0% | −137.3% | −53.3% | −42.0% | −33.0% | −295.6% | — | 3.9% | −50.0% |
| Return on invested capital (ROIC) | — | — | — | −528.6% | — | — | — | — | −3.4% | −5.4% |
| Return on assets (ROA) | −47.5% | −74.1% | −100.1% | −45.1% | −38.3% | −31.8% | −109.6% | −0.1% | 0.6% | −10.1% |
| Return on tangible assets | −37.6% | −45.9% | −142.9% | −53.9% | −35.1% | −16.6% | −82.4% | −58.2% | 0.7% | −10.2% |
| Free cash flow margin | — | — | — | — | — | — | — | — | 71.3% | 25.6% |
| Income quality (OCF / net income) | — | — | — | — | — | — | — | — | 7.70 | — |
| Financial health | ||||||||||
| Total debt | $20.3M | $24.0M | $27.4M | $30.5M | $32.6M | — | — | $3.4M | $8.43B | $8.98B |
| Cash & short-term investments | $1.11B | $642.3M | $123.1M | $256.0M | $376.6M | $345.3M | $14.6M | $8.1M | $397.0M | $1.91B |
| Net debt | −$1.09B | −$618.3M | −$95.7M | −$225.5M | −$343.9M | −$345.3M | −$14.6M | −$4.7M | $8.04B | $7.07B |
| Debt / equity | 0.02 | 0.04 | 0.30 | 0.12 | 0.09 | — | — | — | 4.44 | 4.40 |
| Debt / assets | 0.02 | 0.03 | 0.17 | 0.10 | 0.08 | — | — | 0.41 | 0.72 | 0.69 |
| Net debt / EBITDA | — | — | — | — | — | — | — | — | 8.47 | 66.73 |
| Current ratio | 22.25 | 15.60 | 2.53 | 9.46 | 13.31 | 31.83 | 6.26 | 11.47 | 1.45 | 3.26 |
| Quick ratio | 22.25 | 15.60 | 2.53 | 9.46 | 13.31 | 31.83 | 6.26 | 11.47 | 1.03 | 2.78 |
| Interest coverage | -75.6 | — | — | -58.6 | -202.2 | -148.1 | -47.7 | -959.0 | -0.7 | -1.0 |
| Working capital | $1.08B | $617.0M | $78.3M | $237.5M | $353.7M | $338.1M | $12.4M | $7.4M | $475.0M | $2.07B |
| Invested capital | −$118.2M | $11.6M | −$4.4M | $26.8M | $24.3M | −$2.9M | −$596,000 | −$9.6M | $9.94B | $9.12B |
| Tangible asset value | $972.1M | $629.8M | $91.3M | $252.4M | $368.2M | $342.4M | $14.0M | −$4.9M | $1.10B | $1.21B |
| Net current asset value | $911.8M | $597.9M | $55.6M | $211.6M | $324.9M | $338.1M | $12.4M | −$5.0M | −$8.35B | −$8.02B |
| Graham number | — | — | — | — | — | — | — | — | $11.13 | — |
| Graham net-net per share | $6.97 | $6.17 | $0.83 | $3.89 | $6.27 | $7.07 | $0.27 | — | −$54.73 | −$66.61 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $22.0M | $22.0M |
| Share buybacks (net) | — | — | — | — | — | — | $0 | $0 | — | — |
| Dividend payout ratio | — | — | — | — | — | — | — | — | 28.9% | — |
| Dividends + buybacks / free cash flow | — | — | — | — | — | — | — | — | 6.1% | 6.3% |
| Capex / revenue | — | — | — | — | — | — | — | — | 44.3% | 23.9% |
| Capex / operating cash flow | — | — | — | — | — | — | — | — | 38.3% | 48.2% |
| Capex / depreciation | 0.94 | 1.42 | 0.44 | 1.82 | 3.33 | 1.66 | 6.08 | 5.58 | 0.26 | 0.43 |
| Stock-based compensation / revenue | — | — | — | — | — | — | — | — | 8.7% | 2.3% |
| SG&A / revenue | — | — | — | — | — | — | — | — | 37.4% | 11.8% |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | — | — | — | — | — | — | 324.2 | 105.3 |
| Days of inventory on hand | — | — | — | — | — | — | — | — | 55.4 | 83.4 |
| Days payables outstanding | 1,304.3 | 2,400.1 | 2,090.9 | 506.9 | 1,253.2 | 1,224.3 | 1,194.7 | 2,794,668.1 | 43.5 | 49.9 |
| Cash conversion cycle (days) | — | — | — | — | — | — | — | — | 336.1 | 138.7 |
| Receivables turnover | — | — | — | — | — | — | — | — | 1.13 | 3.47 |
| Payables turnover | 0.28 | 0.15 | 0.17 | 0.72 | 0.29 | 0.30 | 0.31 | 0.00 | 8.39 | 7.31 |
| Inventory turnover | — | — | — | — | — | — | — | — | 6.59 | 4.38 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.11 |
| Average receivables | — | — | — | — | — | — | — | — | $449.5M | $394.0M |
| Average payables | $7.3M | $14.7M | $14.1M | $4.6M | $3.7M | $2.3M | $887,000 | $183.8M | $349.5M | $312.0M |
| Average inventory | — | — | — | — | — | — | — | — | $445.0M | $521.0M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 6.8% | 6.4% |
Computed from DYN's annual financial statements (latest annual report filed March 2, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
DYN valuation and financial ratios
Dyne Therapeutics earned a return on equity of −55.7% in fiscal 2025. It ended the year with $20.3 million of debt and $1.1 billion in cash and short-term investments, a net cash position of $1.1 billion.
See the DYN income statement, the DYN chart for price history, or the DYN stock overview for the latest quote and news.
DYN key metrics FAQ
What is Dyne Therapeutics's return on equity?
Dyne Therapeutics's return on equity (ROE) was −55.7% in fiscal 2025: net income of -$446.2 million on average shareholders' equity of $801.0 million.
How much debt does Dyne Therapeutics have?
Dyne Therapeutics had total debt of $20.3 million at the end of fiscal 2025, a debt-to-equity ratio of 0.02 and more cash than debt.
What is Dyne Therapeutics's free cash flow yield?
Dyne Therapeutics generated -$405.1 million of free cash flow in fiscal 2025, a free cash flow yield of −16.1% on its market value at year-end ($2.5 billion).
What is Dyne Therapeutics's current ratio?
Dyne Therapeutics's current ratio was 22.25 at the end of fiscal 2025: current assets were 22.25 times current liabilities.